Go Pro
NYSE:NVO

Novo Nordisk A/S Q2 2026 Earnings Report

Novo Nordisk A/S logo
$51.50 +0.54 (+1.06%)
As of 10:55 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Novo Nordisk A/S EPS Results

Actual EPS
N/A
Consensus EPS
$0.77
Beat/Miss
N/A
One Year Ago EPS
N/A

Novo Nordisk A/S Revenue Results

Actual Revenue
N/A
Expected Revenue
$10.89 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

Novo Nordisk A/S Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Wednesday, August 5, 2026
Conference Call Time
7:00AM ET

Conference Call Resources

Novo Nordisk A/S Earnings Headlines

The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.tc pixel
Where Will Novo Nordisk Stock Be in 3 Years?
See More Novo Nordisk A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Novo Nordisk A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Novo Nordisk A/S and other key companies, straight to your email.

About Novo Nordisk A/S

Novo Nordisk A/S (NYSE:NVO) is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments. Novo Nordisk has been a major commercial and scientific driver of GLP-1 receptor agonists, marketed under well-known brand names for glucose control and weight management. In addition to diabetes and obesity medicines, the company supplies treatments for haemophilia and other rare bleeding disorders, as well as growth disorders and hormone replacement therapies. Its offerings combine pharmaceuticals with delivery devices and patient services aimed at improving adherence and outcomes.

Research and development are central to Novo Nordisk’s strategy, with continued investment in next-generation medicines for metabolic, cardiovascular and rare diseases. The company operates global manufacturing and distribution networks and markets its products broadly, with significant commercial operations in the United States, Europe and other international markets. Novo Nordisk also engages in partnerships and licensing arrangements with academic institutions, biotechnology firms and healthcare organizations to support innovation and expand access to therapies.

Leadership is focused on long-term innovation and patient-centric care; the company is led by President and CEO Lars Fruergaard Jørgensen. Novo Nordisk positions itself as a specialist pharmaceutical company with a mission to improve the lives of people with chronic conditions through medical innovation, comprehensive treatment solutions and support services for patients and healthcare providers.

View Novo Nordisk A/S Profile